Editas Medicine (EDIT) Research & Development (2015 - 2025)
Editas Medicine (EDIT) reported Research & Development of $19.8 million for Q3 2025, down 58.49% year-over-year from $47.6 million in Q3 2024, and up 22.21% quarter-over-quarter from $16.2 million in Q2 2025.
Editas Medicine (EDIT) Research & Development (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Research & Development data on file, last reported at $19.8 million in Q3 2025.
- Research & Development for Q3 2025 came in at $19.8 million, down 58.49% year-over-year; the trailing twelve-month figure through Sep 2025 was $111.2 million (down 49.52% YoY), and the FY2024 annual result was $199.2 million, up 12.16% from the prior year.
- Research & Development improved to $19.8 million in Q3 2025 per EDIT's latest filing, from $16.2 million in the prior quarter.
- Over five years, Research & Development peaked at $69.6 million in Q4 2023 and troughed at $16.2 million in Q2 2025.
- A 5-year average of $39.8 million and a median of $40.5 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development jumped 82.04% in 2024, then plunged 70.15% in 2025.
- A 5-year view of Research & Development shows it stood at $37.6 million in 2021, then soared by 38.47% to $52.0 million in 2022, then jumped by 33.77% to $69.6 million in 2023, then plunged by 30.11% to $48.6 million in 2024, then tumbled by 59.32% to $19.8 million in 2025.
- Business Quant data shows EDIT's Research & Development at $19.8 million in Q3 2025, $16.2 million in Q2 2025, and $26.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 19.78 Mn |
| Jun 30, 2025 | 16.18 Mn |
| Mar 31, 2025 | 26.59 Mn |
| Dec 31, 2024 | 48.61 Mn |
| Sep 30, 2024 | 47.64 Mn |
| Jun 30, 2024 | 54.21 Mn |
| Mar 31, 2024 | 48.79 Mn |
| Dec 31, 2023 | 69.56 Mn |
| Sep 30, 2023 | 40.51 Mn |
| Jun 30, 2023 | 29.78 Mn |
| Mar 31, 2023 | 37.80 Mn |
| Dec 31, 2022 | 52.00 Mn |
| Sep 30, 2022 | 41.33 Mn |
| Jun 30, 2022 | 43.66 Mn |
| Mar 31, 2022 | 37.98 Mn |
| Dec 31, 2021 | 37.55 Mn |
| Sep 30, 2021 | 29.27 Mn |
| Jun 30, 2021 | 33.75 Mn |
| Mar 31, 2021 | 41.94 Mn |
| Dec 31, 2020 | 61.50 Mn |